WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017192905) TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/192905    International Application No.:    PCT/US2017/031142
Publication Date: 09.11.2017 International Filing Date: 04.05.2017
IPC:
A61K 31/437 (2006.01), A61K 31/519 (2006.01), A61K 31/00 (2006.01)
Applicants: CONCERT PHARMACEUTICALS, INC. [US/US]; 99 Hayden Avenue, Suite 500 Lexington, MA 02421 (US)
Inventors: WAGNER, Amanda, T.; (US).
CASSELLA, James, V.; (US).
GRAHAM, Philip, B.; (US).
BRAMAN, Virginia; (US).
UTTAMSINGH, Vinita; (US).
VON HEHN, Jana; (US).
HAMILTON, Colleen, E.; (US)
Agent: ABELLEIRA, Susan, M.; (US).
AKHIEZER, Alexander; (US).
BENNETT, Jonathan, D.; (US).
BLOUNT, Jonathan, D.; (US).
CHOI, Philip, S.; (US)
Priority Data:
62/331,827 04.05.2016 US
62/338,869 19.05.2016 US
62/418,774 07.11.2016 US
62/419,237 08.11.2016 US
62/434,404 14.12.2016 US
62/466,358 02.03.2017 US
62/492,758 01.05.2017 US
Title (EN) TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS
(FR) TRAITEMENT DES TROUBLES DE LA CHUTE DES CHEVEUX PAR DES INHIBITEURS DE JAK DEUTÉRÉS
Abstract: front page image
(EN)Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I), or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.
(FR)La présente invention concerne un procédé de traitement chez un sujet de troubles de la chute des cheveux qui sont traités avantageusement par l'administration d'un inhibiteur de JAK1 et/ou JAK2. Le procédé consiste à administrer au sujet une quantité située dans la plage comprise entre environ 4 mg et 50 mg du Composé (I) ou d’un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne également des compositions comprenant le Composé (I) et l'utilisation de telles compositions dans les procédés décrits.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)